Steven Zelenkofske has more than 20 years of biopharmaceutical, medical device and gene therapy industry expertise and more than a decade of cardiovascular academic and clinical experience. He serves as DiNAQOR’s Chief Strategy Officer and serves on the company’s Board of Directors.
An expert in clinical development and adaptive trial design and operations, Dr. Zelenkofske has been responsible for multiple NDA filings and approvals throughout his career. He has held leadership positions at SwanBio Therapeutics, Achillion Pharmaceuticals, uniQure, Regado Biosciences, AstraZeneca, Sanofi-Aventis, and Boston Scientific. His work has spanned numerous therapeutic areas including neurology, immunology, hematology, cardiovascular, metabolic diseases, diabetes, and nephrology.
He holds BS and MS degrees from Emory University and a D.O. from the Philadelphia College of Osteopathic Medicine. He conducted his graduate medical education at the Philadelphia College of Osteopathic Medicine and is board-certified in internal medicine, cardiology, and cardiac electrophysiology.